Inherited kidney disorder

Researchers are testing whether adding atrasentan to standard supportive care improves kidney structure and function in adults with IgA nephropathy, a condition where the immune system damages the kidneys. About 20 participants will take atrasentan 0.75 mg once daily for 52 weeks…

This phase 2 trial is investigating whether an experimental drug called ARGX-121 can improve outcomes for adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants will receive either ARGX-121 or a placebo, while continuing their usual care. The …

This early-phase trial is testing a new cell therapy called GT719 for several immune-mediated kidney diseases, including IgA nephropathy and membranous nephropathy. The therapy uses specially engineered immune cells to target and potentially control the disease. The study will en…

This trial tests the long-term safety and effectiveness of povetacicept, an investigational drug given as a subcutaneous injection, in adults with immunoglobulin A nephropathy (IgAN), a kidney disease that can lead to kidney failure. Participants who completed the earlier parent …

This trial investigates whether specially engineered T cells can safely target and fight lung cancer. Participants have advanced or relapsed lung cancer and receive a single infusion of their own T cells that have been trained to recognize cancer-specific markers. The study aims …

This trial asks whether mycophenolate mofetil (MMF) can help people with IgA nephropathy whose disease hasn't improved with standard care. About 104 adults with biopsy-confirmed refractory IgA nephropathy will be randomly assigned to take either MMF or the steroid prednisolone fo…

This phase 3 trial is testing whether sibeprenlimab, an investigational drug given as an injection every 4 weeks, can help children and adolescents with IgA nephropathy. The study includes about 24 participants aged 2 to 17 with biopsy-confirmed disease. The main goal is to see i…

This early-stage trial is testing whether a single infusion of universal STAR-T cells—a type of engineered immune cell that targets both CD19 and BCMA—can safely and effectively treat two autoimmune kidney diseases: IgA nephropathy and primary membranous nephropathy. The study wi…

This study is testing whether an experimental drug called FXS6837 can safely reduce protein in the urine and help preserve kidney function in people with IgA nephropathy, a disease that can lead to kidney failure. About 60 patients who previously completed a shorter study of FXS6…

This phase II trial tests an experimental drug called QLS7305 in people with several kidney diseases driven by overactivation of the complement system, a part of the immune system. The drug is a small interfering RNA (siRNA) designed to reduce production of complement protein C3,…

This study tests whether bempedoic acid, a drug already approved for high cholesterol, can safely slow the progression of autosomal dominant polycystic kidney disease (ADPKD). About 120 adults with rapidly progressing ADPKD will receive either the drug or a placebo for two years.…

This early-phase trial tests a single infusion of universal CAR-T cells (RD06-05) in 30 children and adolescents with severe autoimmune diseases, including lupus, scleroderma, and kidney inflammation. The cells are designed to target and calm overactive immune cells. The main goa…

This study tests whether a low-carbohydrate, plant-based diet can lower inflammation in people with autosomal dominant polycystic kidney disease (ADPKD). Thirty-six adults will try the special diet and their usual diet in random order, each for 12 weeks. The main goal is to see i…

This Phase 3 trial tests whether BHV-1400 can safely reduce protein in the urine and preserve kidney function in 420 adults with IgA nephropathy. Participants are randomly assigned to receive either the drug or a placebo by injection. The main goal is to see if BHV-1400 lowers pr…

This Phase 2 trial tests SLN12140, an experimental drug, in 48 adults with IgA nephropathy whose disease is not well-controlled by standard treatments. Participants receive different doses of SLN12140 or a placebo for 36 weeks, then all can receive the drug for another year. The …

This study will follow 50 adults with IgA nephropathy who are taking sparsentan. Researchers want to see how the drug affects protein in the urine (albuminuria), a key sign of kidney damage. The study is observational, meaning it just watches what happens in real-world use, witho…

This phase 2 trial tests a combination of two drugs (Benmelstobart and Anlotinib) plus targeted radiation (SBRT) in 29 adults with liver cancer that has spread to a few other spots and no longer responds to first-line treatment. The goal is to see if this triple therapy can slow …

This early-phase study tests a new treatment using specially engineered immune cells (CD19 CAR-γδ T cells) for people with severe autoimmune kidney diseases like lupus nephritis, IgA nephropathy, and membranous nephropathy that haven't responded to standard therapies. About 15 pa…

This early-stage trial tests a drug called NM8074 in 10 adults with IgA Nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug safely reduces protein in the urine, a sign of kidney damage, after 99 days of treatment. Participants must have a…

This study tests an experimental drug called FXS6837 in 60 adults with IgA nephropathy, a kidney disease. Participants will receive either the drug or a placebo for about 6 months. The main goal is to see if the drug lowers protein in the urine, a sign of kidney damage.

This Phase 2 trial tests an experimental drug called HS-10542 in 90 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants will receive either a high dose, low dose, or placebo for a set period. The main goal is to see if the drug reduces prot…

This early study tests a drug called piclidenoson in 5 adult men with Lowe syndrome, a rare genetic disorder that harms the kidneys. The goal is to see if the drug can improve how the kidneys reabsorb important small proteins over 6 months. Researchers will also check safety and …

This study tests whether a 12-month diet low in salt, caffeine, protein, and carbs, but high in potassium and water, can slow kidney cyst growth in 30 adults with ADPKD. Participants are split into diet and regular diet groups. The goal is to see if the diet reduces cyst progress…

This study tests an investigational drug called LP-005 in 46 adults with complement-mediated kidney disease, a condition where the immune system attacks the kidneys. Participants receive the injection alongside their standard care. The goal is to see if the drug can reduce protei…

This study tests whether Shenqi Yishen Granules, a traditional Chinese medicine, can reduce protein in the urine of adults with IgA nephropathy, a kidney disease. Researchers will compare the granules to a placebo in 102 participants over several months. The goal is to see if the…

This Phase 2 study tests an injectable drug called CM313 in 106 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if CM313 is safe and can help control the disease by reducing kidney damage. Participants will receive either CM313 or…

This phase 1 study tests whether VX-407, an experimental drug for polycystic kidney disease, changes how combined oral contraceptives are processed in the body. Healthy women will take VX-407 alongside different birth control pills, and researchers will measure hormone levels in …

This observational study at Sohag University Hospital will look at children from birth to 18 years old who have congenital anomalies of the kidney and urinary tract (CAKUT). Researchers will collect data from medical records and routine follow-ups to describe the types of anomali…

This study will test whether taking apple cider vinegar every day for a short time changes the chemistry of urine in adults, both those with a history of calcium oxalate kidney stones and healthy volunteers. Researchers will measure levels of citrate, pH, calcium, and calcium oxa…

This observational study will measure thyroid hormone levels in stored blood and urine samples from 51 people with severe chronic kidney disease (stages 4 and 5). Researchers aim to understand how these hormones differ in patients with and without polycystic kidney disease. The s…

This study looks at what changes occur in the kidneys, urine, and blood when people with IgA nephropathy (IgAN) experience loin pain. Researchers will use MRI scans and lab tests to compare findings during a pain episode and when pain-free. The goal is to better understand the ca…

This early-stage study tests how a new drug called JMKX003142 interacts with other common medications in 112 healthy Chinese adults. The drug is being developed for autosomal dominant polycystic kidney disease (ADPKD). Researchers will measure how the body processes JMKX003142 wh…

This study will observe 80 adults with IgA nephropathy who are prescribed iptacopan or atrasentan as part of their routine care. Researchers will collect data on patient profiles, treatment patterns, and clinical outcomes over 24 months. The goal is to understand how these drugs …

This early-stage study checks whether a single dose of JMKX003142 affects the heart's electrical activity in 24 healthy Chinese adults. Participants will be randomly assigned to receive the drug or a placebo. The goal is to see if the drug causes any changes in heart rhythm, not …

This phase 1 trial will enroll 8 healthy Chinese men to study how the experimental drug JMKX003142 is absorbed, broken down, and eliminated from the body. Participants will receive the drug in both pill and IV forms, some with a radioactive tracer. The study aims to measure the d…

This early-stage study tests a single injection of RG002C0106 in 24 adults to see how kidney function affects the drug's levels and safety. Participants have either normal kidneys or mild-to-moderate kidney impairment. The goal is to gather basic information, not to treat the dis…

This early-stage study tests how a new drug called JMKX003142 interacts with two common medications—amiodarone (for heart rhythm) and febuxostat (for gout)—in 48 healthy Chinese adults. Participants will take the drugs in sequence to measure how their bodies process them. The goa…